Yuhan Corporation (KRX:000100)
South Korea · Delayed Price · Currency is KRW 94,200
+2,800 (3.06%)
Apr 8, 2026, 3:30 PM KST
Yuhan Revenue
In the year 2025, Yuhan had annual revenue of 2.19T KRW with 5.75% growth. Yuhan had revenue of 546.07B in the quarter ending December 31, 2025, with 10.07% growth.
Revenue
2.19T
Revenue Growth
+5.75%
P/S Ratio
3.20
Revenue / Employee
1.06B
Employees
2,067
Market Cap
7.00T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19T | 118.85B | 5.75% |
| Dec 31, 2024 | 2.07T | 208.81B | 11.23% |
| Dec 31, 2023 | 1.86T | 83.14B | 4.68% |
| Dec 31, 2022 | 1.78T | 88.04B | 5.22% |
| Dec 31, 2021 | 1.69T | 67.95B | 4.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.07T |
| GC Biopharma | 1.99T |
| Chong Kun Dang Pharmaceutical | 1.69T |
| Daewoong Pharmaceutical | 1.57T |
| Hanmi Pharm. | 1.55T |
| Boryung | 1.02T |
| DongKook Pharmaceutical | 926.88B |
| Ildong Pharmaceutical | 566.93B |